Update on the taxoids and other new agents in head and neck cancer therapy

Current Opinion in Oncology

Volumn 10, Issue 3, 1998, Pages 233-241

  Schrijvers, Dirk ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALNORIN; ALPHA INTERFERON; AMONAFIDE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; ISOTRETINOIN; NAVELBINE; PACLITAXEL; PHOTOFRIN II; PLATINUM DERIVATIVE; RHIZOXIN; TAXOID; THYMETAQ; TOPOTECAN; TRIMETREXATE; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG TOXICITY; HEAD CANCER; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NECK CANCER; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SEPSIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING;

EID: 0031833503     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199805000-00010     Document Type: Article

References (58)

1. Devriendt D, Klastersky J: New cytostatic agents for the treatment of head and neck. Acta Otorhinolaryngol Belg 1997, 51:61-68.
2. Eisenhauer EA, Vermorken JB: Review: new cytotoxic drugs. South Am J Cancer 1997, 1:17-32.
3. Gan Y, Wientjes MG, Schuller DE, Au JL: Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 1996, 56:2086-2093.
4. Pulkkinen JO, Elomaa L, Joensuu H, Martikainen P, Servomaa K, Grenman R: Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 1996, 122:214-218.
5. Griffon EG, Merlin JL, Marchai C: In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids. Cancer Lett 1996, 109:23-32.
6. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA: Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996, 56:5198-5204.
7. Gebbia V, Testa A, Cannata G, Gebbia N: Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996, 32:901-902.
8. Breier S, Lebedinsky C, Pelayes L, Nicolaci N, Roffe C, Traine G, Breier V: Phase II study of weekly paclitaxel in previously treated patients [abstract 641]. Ann Oncol 1996, 7(suppl 5):133.
9. Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR: Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology 1997, 54:89-95.
10. Hitt R, Hornedo J, Colomer R, Hidalgo M, Brandariz A, Pena M, Vincent J, Cortes-Funes H: Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol 1997, 24:S58-S64.
11. Frasci G, Comella P, Parziale A, Casaretti R, Daponte A, Gravina A, De Rosa L, Gallipoli A, Comella G: Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study. Ann Oncol 1997, 8:291-293.
12. Benasso M, Numico G, Merlano M, Rosso R, Blengio F: Taxol, cisplatin (CDDP) and fluoruracil (FU) in relapsed squamous-cell carcinoma of the head and neck (SCC-HN): preliminary results of a phase I-II trial [abstract 375]. Ann Oncol 1996, 7(suppl 5):79.
13. Dunphy FR, Boyd JH, Kim HJ, Dunphy CH, Harrison BR, Dunleavy TL, Rodriguez JJ, McDonough EM, Minster JR, Hilton JG: A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer 1997, 79:2016-2023.
14. Fountzilas G, Skarlos D, Athanassiades A, Kalogera Fountzila A, Samantas E, Bacoyiannis C, Nicolaou A, Dombros N, Briasoulis E, et al.: Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1997, 8:451-455.
15. Huber MH, Lee JS, Newman RA, Fossella FV, Wester M, Hong WK, Lippman SM: A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol 1996, 7:59-63.
16. Constenla-Figueiras M, Mel-Lorenzo JR, Garcia-Arroyo FR, Quintero Aldana G, Lorenzo I, Váquez-Estevez S: A phase II study of weekly 1-hour paclitaxel (T) and 24-hour infusion with high-dose fluorouracil (5-FU) with leucovorin (LV) for advanced carcinoma of the head and neck [abstract 376]. Ann Oncol 1996. 7(suppl 5):80.
17. Rothenberg M, Eckhardt J, Weiss G, Rodriguez G, Burris H, Rinalde D, Von Hoff D: Preliminary results of a phase I trial of gemcitabine and paclitaxel in patients with refractory solid tumors. Recent Clinical Advantages with Gemzar 1997, 3:11-14.
18. Hoffmann W, Rodemann HP, Belka C, Budach W, Schmidberger H, Bochtler H, Heinrich V, Bamberg M: Paclitaxel in simultaneous radiochemotherapy of head and neck cancer: preclinical and clinical results. Semin Oncol 1997, 24:S72-S77.
19. Rosenthal DI, Okani O, Truelson JM, Fathallah Shaykh H, Vuitch FM, Gazdar AF, Griener J, Landay M, Mendelsohn D, Tourville J, et al.: Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies. Semin Oncol 1997, 24:S81-S84.
20. Tishler RB, Busse PM, Norris CM, Rossi R, Poulm M, Thornhill L, Costello R, Peters ES, Covelas AD, Posner M: Concomitant paclitaxel and oncedaily radiotherapy in the treatment of head and neck cancer [abstract 1378]. Proc Am Soc Clin Oncol 1997, 16:386a.
21. Conley B, Jacobs M, Suntharalingam M, Zacharski D, Ord RA, Gray W, Aisner J: A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol 1997, 24:S78-S80.
22. Sivasailam S, Aisner J, Castellanos P, Gray W, Hernandez I, Jacobs M, Kearns C, Ord R, Rosen D, Sawyer R. et al.: Pilot trial of weekly cisplatin and paclitaxel combined with radiation therapy in patients with unresectable head and neck squamous cell carcinoma [abstract 1395]. Proc Am Soc Clin Oncol 1997, 16:391a.
23. Wanebo HJ, Chougule P, Akerley W, Koness RJ, McRae R, Nigri P, Leone L, Safran H, Webber B, Cole B: Preoperative paclitaxel, carboplatin and radiation in advanced head and neck (stage III and IV) induced a high rate of complete pathologic response at the primary site and high rate of organ preservation [abstract 1397]. Proc Am Soc Clin Oncol 1997, 16:391a.
24. Dunphy FR, Dunleavy TL, Harrison BR, Boyd JH, Varvares MA, Dunphy CH, Rodriguez JJ, McDonough EM, Minster JR, McGrady MD: Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997, 79:1623-1628.
25. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996, 14:1672-1678.
26. Schöffski P, Wanders J, Catimel G, Heinrich B, Schrijvers D, Gore M, Oulid-Aissa D, Verweij J, EORTC Early Clinical Studies Group: A Promising Regimen for Treatment of Squamous Cell Carcinoma of the Head and Neck: Docetaxel and Cisplatin [abstract 373]. Ann Oncol 1996, 7(suppl 5):79.
27. Posner M, Norris C, Colevas A, Tishler R, Rossi R, Costello R, Anderson J, Poulin M, Thornhill L, Busse P: Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin for curable, locally advanced squamous cell cancer of the head and neck [abstract 1380]. Proc Am Soc Clin Oncol 1997, 16:387a.
28. Burns HA, Field S: Summary of data from in vitro and phase I vinorelbine studies. Semin Oncol 1994, 21(suppl 10):14-20.
29. Schilling T, Fiebig HH, Kerpel-Fronius S, Winterhalter B, Variol P, Tresca P, Heinrich B, Hanauske AR: Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs 1996, 14:371-378.
30. Degardin M, Bastit PH, Rolland F, Armand JP, Chevallier B, Van Glabbeke M, Bourdillet J, Tresca P: Phase II study of vinorelbine in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck [abstract 843]. Eur J Cancer 1997, 33(suppl 8):S187.
31. Oliveira J, Geoffrois L, Rolland F, Degardin M, Armand JP, Tresca P, Boudillet J, Lentz MA, Fumoleau P, EORTC-CSG/EORTC-ECSG: Phase II study of navelbine in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck (SCCHN) untreated by chemotherapy and with lesions within previously irradiated fields [abstract 371]. Ann Oncol 1996, 7(suppl 5):78.
32. Canfield VA, Saxman SB, Kolodziej MA, Harrison-Mann B, Loehrer PJ, Vokes EE: Phase II trial of vinorebline in advanced or recurrent squamous cell carcinoma of the head and neck [abstract 1382]. Proc Am Soc Clin Oncol 1997, 16:387a.
33. Rivera F, Lopez-Brea M, Lopez-Vega JM, Pascual C, Rubio A, Rama J, Pérez-Lastra L, Sanz-Ortis J: High activity of UFT vinorelbine and cisplatin (UFTVP) as Induction chemotherapy for locally advanced squamous cell head and neck carcinoma [abstract 1376]. Proc Am Soc Clin Oncol 1997, 16:386a.
34. McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J: Multicentre phase II pharmacological evaluation of rhizoxin. EORTC early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. Br J Cancer 1996, 74:1944-1948.
35. 2 as a 3-hour infusion in hypertonic saline for six cycles, has an antitumour activity comparable with combination regimens in locally advanced HNC with a different pattern of toxicity.
36. Planting AST, Vermorken JB, Catimel G, de Mulder PHM, de Graeff A, Oster W, Hoppener F: Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer [abstract 374]. Ann Oncol 1996, 7(suppl 5):79.
37. Burris H, Vogel CL, Schwarz M, Castro D: Intradose (Cisplatin/Epinephrine) injectable gel for intratumoral therapy of accessible solid tumors including head and neck squamous cell carcinoma [abstract 593]. Ann Oncol 1996, 7(suppl 5):123.
38. Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Dunnington JS, Hong WK: A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 1996, 19:379-382.
39. Bandealy M, Hanna M, Arquette M, McClean J, Monaco F, Sandier AB: Phase II trial of ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a Hoosier Oncology Group trial [abstract 1412]. Proc Am Soc Clin Oncol 1997, 16:396a.
40. Gaspar C, Berrocal A, Muñoz MA, Burriel C, Camps C, Prats C, Estelles E, Guillem V: Phase II study of cisplatin and ifosfamide as neoadjuvant therapy in advanced carcinomas of head and neck [abstract 392]. Ann Oncol 1996, 7(suppl 5):83.
41. Bruno M, Araujo C: Ifosfamide/Mesna Plus Carboplatin as Neoadjuvant Therapy for Stage I Head and Neck Cancer [abstract 396]. Ann Oncol 1996, 7(suppl 5):84.
42. Rivera F, López-Vega JM, López Brea M, Rubio A, Rodriguez J, Rama J, Sanz-Ortiz J: A phase II study of ifosfamide and carboplatin (IJ) as induction chemotherapy for locally advanced squamous cell head and neck carcinoma (SCHNC) [abstract 390]. Ann Oncol 1996, 7(suppl 5):82
43. Berdah JF, Bareille-St Gaudens A, Genet D, Germain T, Rhein B, Fruge F, Clavere P, Roullet B, Daban A, Tubiana-Mathieu N, C.R.O.C.O. group: Ifosfamide plus vindesine as a phase II study in recurrent or metastatic head and neck cancers [abstract 395]. Ann Oncol 1996, 7(suppl 5):83.
44. Fischel JL, Formento P, Etienne MC, Spector T, Renee N, Milano G: Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Pharmacol 1997, 53:1703-1709.
45. Feliu J, Gonzalez-Baron M, Zamora P, Garcia-Alfonso P, Garcia-Giron C, Blanco E, Belon J, Garrido P, Jara C, Ruiz A, Vincent JM, Espinosa E: Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology 1997, 54(suppl 1):30-37.
46. White RM: A phase I study of methotrexate administration following 5-fluorouracil. Am J Clin Oncol 1996, 19:492-499.
47. Belani CP, Aqarwala S, Johnson J, Cohn A, Bernstein J, Langer C, Jones V, White C, Lob K, White D, et al.: A phase II trial of Thymetaq TM(AG337) in patients with squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1997, 16:387a.
48. Cvitkovic F, Mita M, Mahjoubi R, Vannetzel JM, Gill J, Oster W, Habboubi N: Trimetrexate (TMTX) modulation of 5-Fluorouracil/Leucovorin (5-FU/LCV) in untreated head and neck cancer [abstract 386]. Ann Oncol 1996, 7(suppl 5):82.
49. Shewach DS, Lawrence TS: Gemcitabine and radiosensitization in • human tumor cells. Invest New Drugs 1996, 14:257-263. Gemcitabine is a potent radiosensitizer when tested in vitro in human head and neck cancer cell lines at concentrations that are 1000 times lower than plasma levels obtained with this drug.
50. Eisbruch A, Shewach DS, Urba S, Wolf GT, Bradford CR, Marentette LJ, Terrell JE, Hogikuan ND, Esclamado RM, Lawrence TS: Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: high mucosal and pharyngeal toxicity [abstract 1377]. Proc Am Soc Clin Oncol 1997, 16:386a.
51. Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Sue E, Marty M, Herait P, Mahjoubi M, Armand JP: High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol 1997, 15:1080-1086.
52. Robert F, Soong SJ, Wheeler RH: A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Am J Clin Oncol 1997, 20:298-302.
53. Smith R, Lew D, Rodriguez G, Taylor S, Schuller D, Ensley J: Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. A phase II southwest oncology group study. Invest New Drugs 1996, 14:403-407.
54. Leaf AN, Neuberg D, Schwartz EL, Wadler S, Ritch PS, Dutcher JP, Adams GL: An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group. Invest New Drugs 1997, 15:165-172.
55. Andreadis C, Nouratidou D, Sideras T, Kasfikis D, Bishiniotis T: Phase III study of 5-FU plus cisplatin with or without alpha-interferon (alpha-IFN) in advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract 384]. Ann Oncol 1996, 7(suppl 5):81.
56. Gravis G, Pech-Gourgh F, Viens P, Genre D, Bertucci F, Camerlo J, Alzieu C, Maraninchi D: Phase II study of 13 cis-retinoic-acid (13-cRA) + interferon (INF) and cisplatin (CDDP) for advanced head and neck squamous cell carcinoma [abstract 389]. Ann Oncol 1996, 7(suppl 5):82.
57. Skvortsova I, Skvortsov S, Kuznetsova N, Pustoshilova N, Masycheva V: Clinical toxicity of new drug alnorin in patients with head and neck cancer [abstract 400]. Ann Oncol 1996, 7(suppl 5):84.
58. Savary JF, Monnier P, Fontolliet C, Mizeret J, Wagnieres G, Braichotte D, van den Bergh H: Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch Otolaryngol Head Neck Surg 1997, 123:162-168.